AC
LLY icon

Abbrea Capital’s Eli Lilly LLY Stock Holding History

Abbrea Capital’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$8.67M Sell
9,579
-75
-0.8% -$60K 1.15% 24
2024
Q1 		$7.51M Buy
9,654
+228
+2% +$162K 0.99% 26
2023
Q4 		$5.5M Buy
9,426
+383
+4% +$224K 0.79% 30
2023
Q3 		$4.86M Sell
9,043
-218
-2% -$112K 0.77% 32
2023
Q2 		$4.34M Buy
9,261
+172
+2% +$72.1K 0.67% 36
2023
Q1 		$3.12M Sell
9,089
-130
-1% -$43.8K 0.53% 49
2022
Q4 		$3.37M Buy
9,219
+98
+1% +$34.7K 0.61% 44
2022
Q3 		$2.95M Sell
9,121
-142
-2% -$45K 0.56% 43
2022
Q2 		$3M Buy
9,263
+30
+0.3% +$9.01K 0.5% 51
2022
Q1 		$2.64M Hold
9,233
– – 0.37% 62
2021
Q4 		$2.55M Buy
9,233
+338
+4% +$85.7K 0.34% 64
2021
Q3 		$2.06M Sell
8,895
-252
-3% -$62.2K 0.31% 72
2021
Q2 		$2.1M Buy
9,147
+220
+2% +$44.2K 0.32% 70
2021
Q1 		$1.67M Buy
8,927
+167
+2% +$32.7K 0.28% 79
2020
Q4 		$1.48M Buy
8,760
+23
+0.3% +$3.43K 0.26% 77
2020
Q3 		$1.29M Sell
8,737
-277
-3% -$42.9K 0.27% 79
2020
Q2 		$1.48M Buy
9,014
+116
+1% +$17.8K 0.34% 72
2020
Q1 		$1.23M Buy
8,898
+1,083
+14% +$149K 0.33% 72
2019
Q4 		$1.03M Sell
7,815
-45
-0.6% -$5.22K 0.22% 95
2019
Q3 		$879K Buy
7,860
+2,430
+45% +$271K 0.2% 100
2019
Q2 		$602K Sell
5,430
-106
-2% -$12.5K 0.15% 120
2019
Q1 		$718K Buy
5,536
+601
+12% +$73.1K 0.21% 102
2018
Q4 		$571K Buy
4,935
+225
+5% +$25.1K 0.19% 106
2018
Q3 		$505K Buy
4,710
+635
+16% +$63.5K 0.15% 116
2018
Q2 		$348K Sell
4,075
-178
-4% -$14.6K 0.11% 131
2018
Q1 		$329K Buy
4,253
+1,593
+60% +$128K 0.11% 136
2017
Q4 		$225K Buy
2,660
+197
+8% +$16.8K 0.08% 149
2017
Q3 		$211K Hold
2,463
– – 0.08% 149
2017
Q2 		$203K Buy
2,463
+60
+2% +$4.89K 0.08% 143
2017
Q1 		$202K Buy
+2,403
New +$192K 0.08% 140

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Abbrea Capital's LLY Position: Q2 2024 in Review

Abbrea Capital reduced its Eli Lilly (LLY) stake by 0.78% in Q2 2024, selling an estimated $60K and leaving 9,579 shares worth $8.67M. The position accounts for 1.15% of the portfolio, ranked #24.

Abbrea Capital first reported a position in LLY in Q1 2017 and has held it in 30 quarters since. 3,565 funds tracked by Wall St. Rank hold LLY as of Q2 2024.

  • Abbrea Capital held 9,579 shares of Eli Lilly worth $8.67M as of Q2 2024.
  • Abbrea Capital sold 75 Eli Lilly shares in Q2 2024, an estimated $60K.
  • Eli Lilly made up 1.15% of Abbrea Capital's portfolio in Q2 2024, its #24 holding.
  • Abbrea Capital first reported a position in Eli Lilly in Q1 2017 and has held it in 30 quarters since.
  • 3,565 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.